Market Intelligence, Clinical Progress, and High-Purity Reagents for Hippo Pathway Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TEAD2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TEAD2 Recombinant Protein (Full-Length & YAP-Binding Domain Truncations). High purity (>95%), Endotoxin <1 EU/µg, Sequence Verified. HEK293 Expressed. | View TEAD2 Products |
| Mutant Panel | TEAD2 Mutant Proteins (e.g., C359S palmitoylation-deficient). For mechanism-of-action and resistance studies. | View TEAD2 Products |
| Gene Delivery | TEAD2 Premade ORF Lentivirus. Full-length human ORF for stable cell line generation and reporter assays. | View TEAD2 Products |
| Benchmark Ab | Anti-TEAD2 Recombinant Antibody (ChIP/Western grade). Sequence verified positive control. | View TEAD2 Products |
| Validator | TEAD2 siRNA Set. For knockdown verification and assay specificity controls. | View TEAD2 Products |
| Paralog Control | TEAD1 Recombinant Protein. High-homology paralog for selectivity counter-screening. | View TEAD1 Products |
| Binding Partner | YAP1 Recombinant Protein (Full-Length & WW Domain). Essential for YAP-TEAD2 PPI assays. | View YAP1 Products |
| Pathway Competitor | VGLL4 Recombinant Protein. Competes with YAP for TEAD binding; negative control for PPI assays. | View VGLL4 Products |
| Compensatory Paralog | TEAD4 Recombinant Protein. For pan-TEAD assay panels and selectivity profiling. | View TEAD4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Paralog Selectivity (TEAD1/2/3/4) | TEAD family protein panel (TEAD1/2/4) available with >95% purity; sequence verified for selectivity panels. |
| Palmitoylation Site Mechanism | TEAD2 Wild-Type & C359S mutant proteins for covalent inhibitor validation; endotoxin controlled. |
| YAP/TEAD PPI Disruption | Full-length & YAP-binding domain truncations; HEK293 expressed for native folding; suitable for TR-FRET/AlphaScreen. |
| DNA-Binding Inhibition Screening | TEA Domain (DNA-binding domain) construct available for EMSA/FP assays. |
| Cellular Target Engagement | Lentivirus for stable TEAD2 overexpression; compatible with 8xGTIIC luciferase reporter assays. |
| Lack of Controls / False Positives | Sequence-verified anti-TEAD2 recombinant antibody and validated siRNA included for specificity controls. |
Live TEAD2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TEAD2-targeted therapeutics is intensifying, with major players shifting focus from pan-TEAD inhibitors to paralog-selective strategies. First-generation molecules targeting the auto-palmitoylation pocket (e.g., VT3989, IK-930) are entering Phase I/II trials for NF2-mutant mesothelioma and solid tumors. The next wave of R&D includes highly selective allosteric inhibitors, YAP-TEAD PPI disruptors, and pan-TEAD PROTAC degraders. Combination strategies with KRAS, MEK, or EGFR inhibitors are being explored to overcome resistance. Emerging resistance mutations (e.g., at palmitoylation site) will drive demand for mutant protein panels.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Palmitoylation Inhibitor) | Vivace Therapeutics (VT3989), Bayer (IK-930), Ikena Oncology | NF2-mutant mesothelioma, solid tumors | Selectivity Assay (Need WT vs C359S TEAD2 & paralog panel) |
| Small Molecule (PPI Disruptor) | iTeos (EOS-615), Novartis, SpringWorks, BioNTech | Solid tumors (CRC, melanoma) | YAP-TEAD2 TR-FRET (Need purified YAP1 & TEAD2 proteins) |
| PROTAC / Degrader | Emerging biotech programs | Refractory solid tumors | Degradation tracking (Need specific antibodies & cell lines) |
| Peptide / Macrocycle | Peptidream, preclinical platforms | Oncology | PPI disruption & intracellular stability (Need lentivirus & cell-based reporter) |